Precision BioSciences, Cellectis Settle Longtime Patent Feud

Law360, New York (January 31, 2014, 6:20 PM EST) -- Precision BioSciences Inc. and Cellectis SA have reached a deal to cross-license certain genome engineering patents in order to settle ongoing litigation, the two biopharmaceutical companies said Thursday.

The settlement brings to an end the companies’ court battles, centered in North Carolina and Delaware federal courts, in which Durham, N.C.-based Precision and Paris-based Cellectis each sought rulings that the other company infringed its patents covering meganucleases, or “DNA scissors.” The companies will drop all of the pending litigation as part of the cross-licensing agreement.

“This agreement...
To view the full article, register now.